<DOC>
	<DOCNO>NCT00076557</DOCNO>
	<brief_summary>In study modify virus call adeno-associated virus ( AAV ) use transfer normal gene human clot factor IX patient severe hemophilia B ( AAV human Factor IX vector ) . Gene therapy new medical technique use number clinical study diseases cancer cystic fibrosis . At time , U.S. Food Drug Administration approve gene transfer product commercial use . To date , 8 subject receive AAV vector muscle hemophilia B trial intramuscular injection , , date , 6 subject treat AAV vector current hemophilia B liver trial . Eleven cystic fibrosis subject receive AAV vector nasal sinuses lung date . In study , AAV human Factor IX vector inject liver use catheter insert large blood vessel ( call proper hepatic artery right hepatic artery ) .</brief_summary>
	<brief_title>Safety New Type Treatment Called Gene Transfer Treatment Severe Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Males severe hemophilia B Factor IX activity level &lt; 1 % normal . Life expectancy &gt; 1 year . Age &gt; 18 year old . Ability give inform consent . Greater twenty exposure day treatment Factor IX protein . No history presence inhibitor Factor IX protein . Subjects must able receive Factor IX protein home infusion protocol . Subjects must normal protime ( PT ) . Hepatitis C infect subject evaluate liver fibrosis base liver biopsy data grade scale 0â€“4 ( Poynard et . al. , 1997 ) . Subjects Hepatitis C antibody RNA positive liver biopsy within last 36 month require one . Subjects must low AAV titer .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2004</verification_date>
	<keyword>Hemophilia B</keyword>
	<keyword>Factor IX</keyword>
	<keyword>Gene Transfer</keyword>
	<keyword>Adeno-Associated Virus ( AAV )</keyword>
</DOC>